2-[(2R,6S)-2,6-dimethylpiperazin-1-yl]ethanol | 1258073-92-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[(2R,6S)-2,6-dimethylpiperazin-1-yl]ethanol
• 英文别名: 2-(cis-2,6-dimethylpiperazin-1-yl)ethan-1-ol；2-((2S,6R)-2,6-dimethylpiperazin-1-yl)ethanol
• CAS: 1258073-92-5
• 化学式: C₈H₁₈N₂O
• 分子量: 158.244
• InChiKey: DKRGVNOXWNPGBV-OCAPTIKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [1-[(3R,5R)-4-(4-chlorophenyl)sulfonyl-5-(cyclopropylmethyl)morpholin-3-yl]cyclopropyl] carbonochloridate 、 2-[(2R,6S)-2,6-dimethylpiperazin-1-yl]ethanol 以 二氯甲烷 为溶剂， 生成 (3S,5R)-1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl 4-(2-hydroxyethyl)-3,5-dimethylpiperazine-1-carboxylate
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors

  摘要：

  Design and synthesis of cis-2,6-disubstituted N-arylsulfonyl morpholines as novel gamma-secretase inhibitors for the potential treatment of Alzheimer's disease (AD) is reported. Several different small alkyl groups are installed on the left-hand side to lower the CYP3A4 liability while maintaining excellent in vitro potency. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.028

文献信息

• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION COMME MÉDICAMENTS THÉRAPEUTIQUES
  申请人：DONG-A SOCIO HOLDINGS CO LTD

  公开号：WO2017039331A1

  公开（公告）日：2017-03-09

  The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

  本发明提供了一种杂环化合物、其立体异构体、对映异构体或药用可接受的盐，这些化合物能够调节Mer受体酪氨酸激酶（MERTK）的活性。本发明还提供了这些化合物的药物组合物、制备所述化合物的方法以及将这些化合物用作药物的应用。本发明针对的是具有显著活性的MERTK抑制性化合物，因此具有在癌症和任何与MERTK调控失调相关的疾病中进行药物干预的卓越潜力。
• Heteroaryl compounds and their use as therapeutic drugs
  申请人：Dong-A Socio Holdings Co., Ltd.

  公开号：US10125118B2

  公开（公告）日：2018-11-13

  The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

  本发明提供了能够调节Mer受体酪氨酸激酶（MERTK）活性的杂环化合物、其立体异构体、对映体或药学上可接受的盐。本发明还提供了其药物组合物、制备上述化合物的方法以及此类化合物作为药物的用途。 本发明涉及具有显著效力的 MERTK 抑制性化合物，因此在对癌症和任何其他与 MERTK 失调有关的疾病进行药物干预方面具有突出的潜力。
• HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS
  申请人：Dong-A Socio Holdings Co., Ltd.

  公开号：EP3344613A1

  公开（公告）日：2018-07-11